Calidi Biotherapeutics, Inc. (CLDI)
CIK 1855485 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 2.6M shares as of Aug 10, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series J Warrants To Purchase Common Stock | 755.9M | $4 | — | — |
| Series L Warrants To Purchase Common Stock | 755.9M | $4 | — | — |
| Series K Warrants To Purchase Common Stock | 755.9M | $4 | — | — |
| Series I Warrants To Purchase Common Stock | 215.7M | $8 | — | — |
| Underwriter Warrants To Purchase Common Stock | 37.8M | $10 | — | — |
| Series H Warrants To Purchase Common Stock | 34.4M | $8 | — | — |
| Series G Warrants To Purchase Common Stock | 31.5M | $8 | — | — |
| Representative Warrants To Purchase Common Stock | 10.8M | $48 | — | — |
| Public Warrants To Purchase Common Stock | 6.0M | $22080000 | — | — |
| Series A Warrants To Purchase Common Stock | 3.4M | $291.84 | — | — |
| Warrants To Purchase Restricted Shares One | 3.1M | $364.8 | — | — |
| Placement Agent Warrants To Purchase Common Stock Five | 1.6M | $156 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 58,235 underlying shares, as reported Jul 26, 2024 (10-Q).
Reported exercise price: $1.14 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 2.6M = 2.6M O/S + 58,235 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 13, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 2.6M | Aug 10, 2026 |
| + Series J Warrants To Purchase Common Stock (if exercised) | 755.9M | Jun 30, 2026 |
| + Series L Warrants To Purchase Common Stock (if exercised) | 755.9M | Jun 30, 2026 |
| + Series K Warrants To Purchase Common Stock (if exercised) | 755.9M | Jun 30, 2026 |
| + Series I Warrants To Purchase Common Stock (if exercised) | 215.7M | Jun 30, 2026 |
| + Underwriter Warrants To Purchase Common Stock (if exercised) | 37.8M | Jun 30, 2026 |
| + Series H Warrants To Purchase Common Stock (if exercised) | 34.4M | Jun 30, 2026 |
| + Series G Warrants To Purchase Common Stock (if exercised) | 31.5M | Jun 30, 2026 |
| + Representative Warrants To Purchase Common Stock (if exercised) | 10.8M | Jun 30, 2026 |
| + Public Warrants To Purchase Common Stock (if exercised) | 6.0M | Jun 30, 2026 |
| + Series A Warrants To Purchase Common Stock (if exercised) | 3.4M | Jun 30, 2026 |
| + Warrants To Purchase Restricted Shares One (if exercised) | 3.1M | Jun 30, 2026 |
| + Placement Agent Warrants To Purchase Common Stock Five (if exercised) | 1.6M | Jun 30, 2026 |
| Fully diluted estimate | 2.61B | +101075.3% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $21.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 6 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full CLDI workspace
Free to use. No account, no card.